RECURRENT NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Target CAR T-Cells offer new hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune booster: personalized NK cells aim to wipe out blood cancer after transplant
Disease control Recruiting nowThis phase 2 trial tests whether giving patients their own personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill any remaining cancer cells. The study includes 100 people with various blood cancers like leukemia, lymphoma, and multipl…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for young cancer patients: experimental drug targets recurrent tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Engineered immune cells take on HIV-Linked cancers in first human trial
Disease control Recruiting nowThis study tests a CAR-T cell therapy (axicabtagene ciloleucel) in 20 HIV-positive adults whose aggressive B-cell lymphoma has come back or stopped responding to standard treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells. The …
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Triple-Target CAR t cells take on tough blood cancers
Disease control Recruiting nowThis early-phase trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The ther…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC